Proton therapy

Mevion Introduces New MEVION S250-FIT Proton Therapy System

Retrieved on: 
Friday, October 21, 2022
Research, Medical Devices, Other Health, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Proton, LinkedIn, Transform, Hospital, Science, FLASH, Integration, LINAC, Patient, Research, Entrepreneurship, Annual general meeting, Multimedia, Harvard Medical School, Partnership, Varian Medical Systems, Cancer, Technology, C. C. Wang, Proton therapy, MD, Scan (company), Massachusetts General Hospital, Doctor of Philosophy, Industry, CEO, IGRT, Central Waqf Council, FIT, ARC, Radiation, Exhibition, Intensity, Mass, Medical imaging

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, today introduced its new product, the MEVION S250-FIT Proton Therapy System.

Key Points: 
  • Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, today introduced its new product, the MEVION S250-FIT Proton Therapy System.
  • View the full release here: https://www.businesswire.com/news/home/20221021005026/en/
    The MEVION S250-FIT Proton Therapy System (Photo: Business Wire)
    Enabled by the worlds smallest self-shielded proton accelerator from Mevion, the MEVION S250-FIT will be the first and only full proton therapy system that can fit in an existing LINAC vault.
  • Mevion will officially debut the MEVION S250-FIT Proton Therapy System at ASTROs 64th Annual Meeting in San Antonio, TX.
  • *The MEVION S250-FIT Proton Therapy System, FLASH therapy, online adaptive therapy, and ARC therapy are not yet available for clinical use.

American Shared Hospital Services to Present at the LD Micro Main Event XV

Retrieved on: 
Monday, October 17, 2022
SAN, CA, CFO, Radiosurgery, NYSE, Dream, LD, Index, Pectus carinatum, Malignancy, Company, Proton therapy, CEO, Trigeminal neuralgia, IGRT, AMS, GLOBE, IMRT, Medical imaging

SAN FRANCISCO, CA, Oct. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment, facilities, and services, today announced that it will be presenting at the15th Annual Main Event being held on October 25-27, 2022 at the Luxe Sunset Boulevard Hotel, Los Angeles, CA. Ray Stachowiak, CEO, and Craig Tagawa, President and CFO, will present a corporate overview and meet with investors throughout the conference.

Key Points: 
  • Ray Stachowiak, CEO, and Craig Tagawa, President and CFO, will present a corporate overview and meet with investors throughout the conference.
  • The 2022 LD Micro Main Event XV will be held at the Luxe Sunset Boulevard Hotel in Los Angeles from October 25th to the 27th.
  • This three-day, investor conference is expected to feature around 200+ companies, presenting in half-hour increments, as well as private meetings.
  • [email protected]
    LD Micro aims to be the most crucial resource in the micro-cap world.

Japan Proton Therapy Market Report 2022: Featuring IBA Proton Therapy, Varian Medical Systems & Elekta - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 19, 2022
Biotechnology, Radiology, Health, Oncology, Proton, Quality of life, Pancreatic cancer, Prostate cancer, CAGR, Neoplasm, Patient, Industry, HCC, Technology, Lung cancer, Proton therapy, CNS, Radiation, Head and neck cancer, Central nervous system, Hepatocellular carcinoma, COVID-19, Medical imaging, Growth, Cancer

The "Japan Proton Therapy Market, Share, Forecast 2022-2027, Industry Trends, Growth, Size, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Japan Proton Therapy Market, Share, Forecast 2022-2027, Industry Trends, Growth, Size, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Japan Proton Therapy Market value will be US$ 8.6 Billion by 2027.
  • Over the years, various techniques for cancer treatment have emerged, such as chemotherapy, surgery, and proton therapy.
  • According to the publisher report, Japan Proton Therapy Industry is expected to grow with a CAGR of 5.9% during 2021-2027.

CIVCO Radiotherapy to Exhibit Most Recent Innovations at ASTRO Annual Meeting

Retrieved on: 
Monday, October 17, 2022
One Solution, PRO, BOARD, Risk, Patient, AND, Comfort, Hitachi, IBA, Immobilization, Proton therapy, Pro-form, Radiation therapy, Pediatrics, Adult, Skin, Radiation, ALL, EVOLVE, Solution, RT, Medical imaging, Medical device

CORALVILLE, Iowa, Oct. 17, 2022 /PRNewswire/ -- CIVCO Radiotherapy, the leading global provider of high quality, innovative, patient-centric radiotherapy solutions, will feature the TotalRT All in One Solution along with several innovative solutions in booth #3766 at the ASTRO Annual Meeting in San Antonio, Texas, October 23-25, 2022.

Key Points: 
  • CORALVILLE, Iowa, Oct. 17, 2022 /PRNewswire/ --CIVCO Radiotherapy, the leading global provider of high quality, innovative, patient-centric radiotherapy solutions, will feature the TotalRT All in One Solution along with several innovative solutions in booth #3766 at the ASTRO Annual Meeting in San Antonio, Texas, October 23-25, 2022.
  • TheTotalRT Platform is designed to quickly adapt CIVCO RT's positioning and immobilization solutions to radiotherapy clinical setup and treatment needs, providing an all in one solution.
  • This pediatric solution compliments CIVCO RT's current adult ProForm series and is available for CT & MR imaging and proton & photon treatment.
  • COPYRIGHT2022.CIVCOIS AREGISTERED TRADEMARKSOFCIVCO MEDICAL SOLUTIONS.CIVCO RT, CIVCO RADIOTHERAPY, EVOLVE, PROFORM,AND WING BOARD ARETRADEMARKSOF MEDTEC LLC.ALL OTHER TRADEMARKS ARE PROPERTY OF THEIR RESPECTIVE OWNERS.

Instituto Europeo di Oncologia in Milan in Italy selects RayStation and RayCare for their proton center

Retrieved on: 
Friday, September 23, 2022
RaySearch Laboratories, Workflow, CEO, Proton, Radiation, Solution, Proton therapy, IEO, IBA, Photon, Patient, Medical imaging

STOCKHOLM, Sept. 23, 2022 /PRNewswire/ --RaySearch Laboratories AB (publ) announces that Instituto Europeo di Oncologia (IEO) in Milan has placed an order for RayStation* treatment planning system and the oncology information system RayCare*, to be used for radiation treatment with protons.

Key Points: 
  • STOCKHOLM, Sept. 23, 2022 /PRNewswire/ --RaySearch Laboratories AB (publ) announces that Instituto Europeo di Oncologia (IEO) in Milan has placed an order for RayStation* treatment planning system and the oncology information system RayCare*, to be used for radiation treatment with protons.
  • The center, which uses a combination of different radiation machines, will take an IBA proton machine in clinical use in the autumn of 2023 and for this reason, they have chosen to extend their use of RayStation and also add RayCare.
  • The combination of RayStation and RayCare together with an IBA machine provides a more integrated and unified solution throughout the complete workflow compared to other solutions.
  • Johan Lf, Founder and CEO, RaySearch, says: "IEO Milano is a world-renowned center with long experience from using RayStation.

TAE Life Sciences Sponsored Study Details Results of Proton Boron Fusion Therapy Biological Effectiveness

Retrieved on: 
Thursday, September 22, 2022
University, Biotechnology, Education, Health, Publishing, Radiology, Pharmaceutical, Oncology, Communications, Research, Science, Proton, Neutron, DU145, Health, Alpha, X-ray, Journal, MD Anderson Cancer Center, Proton therapy, Department, Sale, Boron, BNCT, PBCT, BPA, Radiation-induced cancer, Research, Neutron capture therapy of cancer, Radiation, Journal of Medical Physics, Economics, Monroe Dunaway Anderson, University, Neoplasm, Immortalised cell line, Patient, Cancer, TLS, CEO, BSH, Technology, LET, Associate professor, Physics, Doctor of Philosophy, Medical physics, DNA repair, DNA, Prostate cancer, Medical imaging

Proton Boron Capture Therapy (PBCT) is a novel approach of particle therapy aimed at enhancing proton biological effectiveness by exploiting the fusion reaction between low-energy protons and a boron drug to destroy cancer cells via radiation delivery.

Key Points: 
  • Proton Boron Capture Therapy (PBCT) is a novel approach of particle therapy aimed at enhancing proton biological effectiveness by exploiting the fusion reaction between low-energy protons and a boron drug to destroy cancer cells via radiation delivery.
  • TAE Life Sciences and the Department of Radiation Physics at The University of Texas MD Anderson Cancer Center conducted a study, Effect of boron compounds on the biological effectiveness of proton therapy , to identify whether PBCT will produce an increased biological effect in destroying the tumor.
  • "TAE Life Sciences is proud of this proton boron fusion study, said Bruce Bauer, PhD, CEO of TAE Life Sciences.
  • TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT).

AccessHope and Fred Hutchinson Cancer Center Announce Foundational Collaboration that Will Expand Access to Cancer Expertise in the Northwestern United States

Retrieved on: 
Wednesday, September 21, 2022
General Health, Health, Oncology, NCI-designated Cancer Center, COVID-19 vaccine, Precision medicine, Radiation, COVID-19, Proton therapy, Twitter, Infection, MD, LLC, Emory University, Knowledge, 2009 Davis Cup, LinkedIn, View, National Cancer Institute, News, Winship Cancer Institute, Immunotherapy, Health equity, Survival, Patient, Haematopoietic system, ZIP, Cancer, City, Fred Hutchinson Cancer Research Center, Physician, NCI, MBA, National Comprehensive Cancer Network, Solution, Seattle Cancer Care Alliance, Science, Emory Healthcare, Research, UW, Hospital, Oncology, City of Hope, Dana–Farber Cancer Institute, Health insurance, Dietary supplement, Pharmaceutical industry, Northwestern Medicine, Health

Through the new collaboration, cancer specialists from Fred Hutch will provide specialized cancer expertise for AccessHopes core services: Accountable Precision Oncology, Expert Advisory Review and Cancer Support Team.

Key Points: 
  • Through the new collaboration, cancer specialists from Fred Hutch will provide specialized cancer expertise for AccessHopes core services: Accountable Precision Oncology, Expert Advisory Review and Cancer Support Team.
  • Ensuring that anyone who is facing a cancer diagnosis has access to leading-edge cancer care is paramount to everything we do at Fred Hutch, explained Tom Purcell, MD, MBA, Chief Medical Officer, Fred Hutchinson Cancer Center.
  • Based in Seattle, Fred Hutch is an independent, nonprofit organization and is the only National Cancer Institute-designated cancer center in Washington.
  • Please note that the organization was renamed Fred Hutchinson Cancer Center in April 2022, following the merger of long-time partners, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance.

NorthStar Medical Radioisotopes and IBA Sign Agreement for Two Additional Rhodotron® Electron Beam Accelerators for Commercial Production of Radioisotopes

Retrieved on: 
Tuesday, September 20, 2022
Oncology, Medical Devices, Health, Radiology, Pharmaceutical, Biotechnology, Health, Actinium-225, Nuclear medicine, Sterilization, Proton therapy, Isotopes of molybdenum, FDA, IBA, Radiopharmaceutical, LLC, Licensure, Reuters, Degenerative disease, Bloomberg, Cancer, Technology, Google Images, B Corporation (certification), NorthStar, Ion Beam Applications, Research, Multimedia, Radionuclide, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20220920005229/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220920005229/en/
    IBA RhodotronTT300-HE electron beam accelerator (Photo: Business Wire)
    The purchase marks a total of five Rhodotron accelerators that NorthStar has purchased from IBA to date.
  • NorthStar previously purchased two electron beam accelerators from IBA in 2019 for the production of Mo-99, and purchased a third accelerator in 2021 for production of the therapeutic radioisotope actinium-225 (Ac-225).
  • The additional accelerators will be used to further expand NorthStars commercial-scale radioisotope production capabilities at its Beloit, Wisconsin headquarters.
  • NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company that manufactures and distributes diagnostic and therapeutic radioisotopes and radiopharmaceuticals.

ProCure Patient Shows Why There's Strength in Cancer Screenings

Retrieved on: 
Tuesday, September 13, 2022
Proton, Health, American Cancer Society, Breast, Radiation, PSA, Center, Proton therapy, Awareness, Brain, Sarcoma, Prostate, Manifest and latent functions and dysfunctions, Degenerative disease, Procurement, Rectum, Neoplasm, Survival, Patient, Extrapyramidal system, Physician, Head, Tissue, Diagnosis, Lung, Prostate cancer, Fatigue, Neck, Cancer, Freedom, Incontinence, Disease, Medical imaging

As we mark Prostate Cancer Awareness Month in September, one New Jersey man's story shows that not only does early detection increase your chance of survival, but it also opens the door to a non-invasive treatment called proton therapy at ProCure.

Key Points: 
  • As we mark Prostate Cancer Awareness Month in September, one New Jersey man's story shows that not only does early detection increase your chance of survival, but it also opens the door to a non-invasive treatment called proton therapy at ProCure.
  • As Kerwick aged, he made a point to get regular PSA screenings for prostate cancer.
  • When one of those regular screenings led to an early-stage prostate cancer diagnosis, Kerwick became a candidate for one of the most advanced forms of radiation therapy at ProCure.
  • Physicians at ProCure use a precisely targeted type of proton therapy called pencil beam radiation, which boosts accuracy compared to standard radiation therapy with its ultra-narrow proton radiation beam.

Renowned Health Leader and Radiation Oncologist Named Senior Vice President and Deputy Chief Clinical Officer at NYU Langone Health

Retrieved on: 
Wednesday, September 7, 2022
Breast cancer, Icahn School of Medicine at Mount Sinai, Collaboration, Inflammatory bowel disease, Cancer, Research, MSKCC, NYU Langone Health, Memorial Sloan Kettering Cancer Center, Proton therapy, Radiation, FGP 227, Department, Radiation therapy, MD, Leadership, Stroke, III, Medical imaging

NEW YORK, Sept. 7, 2022 /PRNewswire/ -- NYU Langone Health today announced the appointment of internationally renowned physician and researcher, Oren Cahlon, MD, as senior vice president and deputy chief clinical officer.

Key Points: 
  • NEW YORK, Sept. 7, 2022 /PRNewswire/ -- NYU Langone Health today announced the appointment of internationally renowned physician and researcher, Oren Cahlon, MD, as senior vice president and deputy chief clinical officer.
  • Dr. Cahlon comes to NYU Langone from Memorial Sloan Kettering Cancer Center (MSKCC), where he was the deputy physician-in-chief for strategic partnerships, senior vice president for clinical business development, and the vice chair of the Department of Radiation Oncology.
  • Dr. Cahlon received his medical degree from Mount Sinai School of Medicine, having graduated top of his medical school class.
  • He went on to complete his internship and residency in radiation oncology at MSKCC and then began his careerat Princeton Radiation Oncology, one of the largest providers of radiation services in New Jersey.